JP2022105084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022105084A5 JP2022105084A5 JP2022072043A JP2022072043A JP2022105084A5 JP 2022105084 A5 JP2022105084 A5 JP 2022105084A5 JP 2022072043 A JP2022072043 A JP 2022072043A JP 2022072043 A JP2022072043 A JP 2022072043A JP 2022105084 A5 JP2022105084 A5 JP 2022105084A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disease
- acid sequence
- amino acid
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023209102A JP7823011B2 (ja) | 2015-03-09 | 2023-12-12 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2025174910A JP2026012786A (ja) | 2015-03-09 | 2025-10-16 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562130076P | 2015-03-09 | 2015-03-09 | |
| US62/130,076 | 2015-03-09 | ||
| JP2022051047A JP7391132B2 (ja) | 2015-03-09 | 2022-03-28 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022051047A Division JP7391132B2 (ja) | 2015-03-09 | 2022-03-28 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023209102A Division JP7823011B2 (ja) | 2015-03-09 | 2023-12-12 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022105084A JP2022105084A (ja) | 2022-07-12 |
| JP2022105084A5 true JP2022105084A5 (enExample) | 2022-11-22 |
| JP7403575B2 JP7403575B2 (ja) | 2023-12-22 |
Family
ID=55863122
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017547456A Pending JP2018509413A (ja) | 2015-03-09 | 2016-03-08 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2021016293A Active JP7050191B2 (ja) | 2015-03-09 | 2021-02-04 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2022051047A Active JP7391132B2 (ja) | 2015-03-09 | 2022-03-28 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2022072043A Active JP7403575B2 (ja) | 2015-03-09 | 2022-04-26 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2023209102A Active JP7823011B2 (ja) | 2015-03-09 | 2023-12-12 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2025174910A Pending JP2026012786A (ja) | 2015-03-09 | 2025-10-16 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017547456A Pending JP2018509413A (ja) | 2015-03-09 | 2016-03-08 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2021016293A Active JP7050191B2 (ja) | 2015-03-09 | 2021-02-04 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2022051047A Active JP7391132B2 (ja) | 2015-03-09 | 2022-03-28 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023209102A Active JP7823011B2 (ja) | 2015-03-09 | 2023-12-12 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2025174910A Pending JP2026012786A (ja) | 2015-03-09 | 2025-10-16 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20160264669A1 (enExample) |
| EP (2) | EP4006051A1 (enExample) |
| JP (6) | JP2018509413A (enExample) |
| KR (1) | KR102720769B1 (enExample) |
| AU (2) | AU2016230827B2 (enExample) |
| CA (1) | CA2978253A1 (enExample) |
| DK (1) | DK3268391T3 (enExample) |
| EA (1) | EA038178B1 (enExample) |
| ES (1) | ES2882999T3 (enExample) |
| HU (1) | HUE056775T2 (enExample) |
| IL (2) | IL254403B (enExample) |
| LT (1) | LT3268391T (enExample) |
| MX (2) | MX386491B (enExample) |
| MY (1) | MY188761A (enExample) |
| PL (1) | PL3268391T3 (enExample) |
| PT (1) | PT3268391T (enExample) |
| SG (2) | SG10201908259WA (enExample) |
| WO (1) | WO2016142782A1 (enExample) |
| ZA (1) | ZA202109042B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106103476B (zh) | 2013-12-24 | 2020-11-27 | 阿尔金克斯有限公司 | FcRn拮抗剂及使用方法 |
| JP6853178B2 (ja) * | 2015-01-30 | 2021-03-31 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＦｃＲｎ抗体およびその使用方法 |
| MX386491B (es) * | 2015-03-09 | 2025-03-18 | argenx BV | Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn. |
| WO2018007999A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| GB201618424D0 (en) * | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
| WO2018193427A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| CN111315772A (zh) | 2017-10-31 | 2020-06-19 | 斯塔顿生物技术有限公司 | 抗apoc3抗体及其使用方法 |
| MA51032A (fr) * | 2017-12-08 | 2021-03-17 | Argenx Bvba | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée |
| JP7486437B2 (ja) | 2018-06-08 | 2024-05-17 | アルジェニクス ビーブイ | 免疫性血小板減少症を治療する組成物及び方法 |
| WO2020148336A1 (en) * | 2019-01-16 | 2020-07-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of agents capable of inducing lc3-associated phagocytosis for treating sustained inflammation in patients suffering from chronic liver disease |
| GB2589049C (en) * | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| BR112021024632A2 (pt) * | 2019-06-07 | 2022-01-18 | Argenx Bvba | Formulações farmacêuticas de inibidores de fcrn adequados para administração subcutânea |
| CN114466663B (zh) * | 2019-07-25 | 2026-01-02 | 建新公司 | 以FcRn拮抗剂治疗抗体介导的障碍的方法 |
| ES2992247T3 (es) | 2020-01-08 | 2024-12-11 | argenx BV | Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo |
| WO2021160116A1 (zh) * | 2020-02-10 | 2021-08-19 | 北京拓界生物医药科技有限公司 | 抗FcRn抗体、其抗原结合片段及其医药用途 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| CA3183153A1 (en) * | 2020-06-17 | 2021-12-23 | Christian HINDERER | Compositions and methods for treatment of gene therapy patients |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| CN117693523A (zh) * | 2021-08-13 | 2024-03-12 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别fcrn的抗体及其用途 |
| KR20250037789A (ko) | 2022-06-15 | 2025-03-18 | 아르젠엑스 비브이 | Fcrn/항원-결합 분자 및 사용 방법 |
| IL320846A (en) * | 2022-11-14 | 2025-07-01 | argenx BV | Fcrn antagonist molecules and methods of use thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5326856A (en) | 1992-04-09 | 1994-07-05 | Cytogen Corporation | Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding |
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6128119A (en) | 1997-01-10 | 2000-10-03 | Asahi Kogaku Kogyo Kabushiki Kaisha | Beam shaping optical system |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| US6725230B2 (en) | 2000-07-18 | 2004-04-20 | Aegis Analytical Corporation | System, method and computer program for assembling process data of multi-database origins using a hierarchical display |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| WO2002043658A2 (en) | 2000-11-06 | 2002-06-06 | The Jackson Laboratory | Fcrn-based therapeutics for the treatment of auto-immune disorders |
| EP1370288B1 (en) | 2000-11-20 | 2012-01-11 | Canadian Blood Services | Method for treating thrombocytopenia with monoclonal ivig |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| CA2487932A1 (en) | 2002-05-30 | 2003-12-11 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
| PT1534335E (pt) | 2002-08-14 | 2012-02-28 | Macrogenics Inc | Anticorpos específicos de fcγriib e processos para a sua utilização |
| CA2832136C (en) | 2002-09-27 | 2015-11-17 | Xencor | Optimized fc variants and methods for their generation |
| ATE480562T1 (de) | 2002-10-15 | 2010-09-15 | Facet Biotech Corp | Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| AU2004204817C1 (en) | 2003-01-13 | 2011-01-20 | Macrogenics, Inc. | Soluble FcyR fusion proteins and methods of use thereof |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| WO2006130834A2 (en) * | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
| CA2682605A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| MX2009012343A (es) | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| CN103755808B (zh) * | 2009-03-25 | 2016-02-10 | 霍夫曼-拉罗奇有限公司 | 抗-α5β1抗体及其应用 |
| US9067997B2 (en) * | 2011-05-25 | 2015-06-30 | Innate Pharma Sa | Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders |
| US9790280B2 (en) * | 2011-10-26 | 2017-10-17 | Elanco Tiergesundheit Ag | Monoclonal canine CD20 antibodies and methods of use |
| EP2780463A4 (en) * | 2011-11-18 | 2015-07-01 | Merck Sharp & Dohme | FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING |
| CN104619722B (zh) * | 2012-06-22 | 2022-10-04 | 达特茅斯大学理事会 | 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途 |
| CN106103476B (zh) * | 2013-12-24 | 2020-11-27 | 阿尔金克斯有限公司 | FcRn拮抗剂及使用方法 |
| MX386491B (es) * | 2015-03-09 | 2025-03-18 | argenx BV | Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn. |
-
2016
- 2016-03-08 MX MX2017011534A patent/MX386491B/es unknown
- 2016-03-08 KR KR1020177027256A patent/KR102720769B1/ko active Active
- 2016-03-08 CA CA2978253A patent/CA2978253A1/en active Pending
- 2016-03-08 DK DK16719896.9T patent/DK3268391T3/da active
- 2016-03-08 IL IL254403A patent/IL254403B/en unknown
- 2016-03-08 JP JP2017547456A patent/JP2018509413A/ja active Pending
- 2016-03-08 MY MYPI2017001178A patent/MY188761A/en unknown
- 2016-03-08 AU AU2016230827A patent/AU2016230827B2/en active Active
- 2016-03-08 EA EA201791984A patent/EA038178B1/ru unknown
- 2016-03-08 US US15/064,195 patent/US20160264669A1/en active Pending
- 2016-03-08 HU HUE16719896A patent/HUE056775T2/hu unknown
- 2016-03-08 EP EP21189336.7A patent/EP4006051A1/en active Pending
- 2016-03-08 EP EP16719896.9A patent/EP3268391B1/en active Active
- 2016-03-08 PT PT167198969T patent/PT3268391T/pt unknown
- 2016-03-08 SG SG10201908259W patent/SG10201908259WA/en unknown
- 2016-03-08 IL IL295425A patent/IL295425A/en unknown
- 2016-03-08 ES ES16719896T patent/ES2882999T3/es active Active
- 2016-03-08 WO PCT/IB2016/000398 patent/WO2016142782A1/en not_active Ceased
- 2016-03-08 SG SG11201707053SA patent/SG11201707053SA/en unknown
- 2016-03-08 PL PL16719896T patent/PL3268391T3/pl unknown
- 2016-03-08 LT LTEPPCT/IB2016/000398T patent/LT3268391T/lt unknown
-
2017
- 2017-09-08 MX MX2021011633A patent/MX2021011633A/es unknown
-
2021
- 2021-02-04 JP JP2021016293A patent/JP7050191B2/ja active Active
- 2021-11-15 ZA ZA2021/09042A patent/ZA202109042B/en unknown
- 2021-12-02 AU AU2021277720A patent/AU2021277720B2/en active Active
-
2022
- 2022-03-28 JP JP2022051047A patent/JP7391132B2/ja active Active
- 2022-04-26 JP JP2022072043A patent/JP7403575B2/ja active Active
-
2023
- 2023-12-12 JP JP2023209102A patent/JP7823011B2/ja active Active
-
2025
- 2025-10-16 JP JP2025174910A patent/JP2026012786A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501725A5 (enExample) | ||
| JP2018509413A5 (enExample) | ||
| JP2025504815A5 (enExample) | ||
| JP2025520420A5 (enExample) | ||
| ES2823950T3 (es) | Moléculas con especificidad para CD45 y CD79 | |
| CA3258002A1 (en) | FCRN BINDING MOLECULES AND METHODS OF USE | |
| RU2005134394A (ru) | Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа | |
| JP2016527187A5 (enExample) | ||
| CA3034480A1 (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
| US20080227704A1 (en) | CXCL13 binding proteins | |
| JP2014520092A5 (enExample) | ||
| JP2018522578A (ja) | ヒト化型親和性成熟抗ＦｃＲｎ抗体 | |
| JPH1087510A (ja) | ナイトロジェンマスタード系抗癌剤と組合わせて使用するための骨髄腫治療剤 | |
| JP2024530152A5 (enExample) | ||
| JP2018524007A (ja) | Ｃｄ２２に結合する抗体分子 | |
| JP2012503977A (ja) | ヒトｉｌ１７に対する抗体およびその使用 | |
| JP2018529313A (ja) | Ｃｄ７９に結合する抗体分子 | |
| WO2010055366A4 (en) | Anti-human il-21 monoclonal antibodies | |
| JP7688805B2 (ja) | 二重特異性抗体 | |
| JP2022521850A5 (enExample) | ||
| HK1207870A1 (en) | Anti-human sema4a antibodies useful to treat disease | |
| JPWO2020004490A5 (enExample) | ||
| WO2020091634A1 (ru) | Моноклональное антитело, которое специфически связывается с cd20 | |
| JP2025507836A (ja) | 骨髄コンディショニング方法 | |
| US20250313644A1 (en) | Antibodies capable of specifically binding tl1a and use thereof |